Home » Topics » Regulatory

Regulatory
RSS

Phase III results indicate Ergoset's effectiveness and safety

July 26, 1996

Leiras claims oral delivery system for oxybutynin chloride

July 26, 1996

Novo Nordisk claims xanomeline as potential urinary bladder disorder treatment

July 26, 1996

Pharmacia & Upjohn introduces new dosage strength for Fragmin

July 26, 1996

SR-140333 claimed as a cardioregulatory drug

July 26, 1996

BES and BENSPM claimed as vascular proliferative disorders treatment

July 26, 1996

Glaxo Wellcome claims GR-79236 for reducing myocardial injury

July 26, 1996

Bifemelane claimed for cerebrovascular disorders treatment

July 26, 1996

CP-122638: Pfizer's potential treatment for non-migraine emesis

July 26, 1996

5-HT3/NK1 antagonist combination effective in emesis treatment and prevention

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...